ClinicalTrials.gg
TerminatedNCT05211284SARONAPLUSUpdated Sep 2, 2025Results posted

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

A Phase 2 interventional study of Saroglitazar Magnesium 4 mg and Placebo in Nonalcoholic Fatty Liver Disease, sponsored by Zydus Therapeutics Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
443rd of 460
4 · median 56
Started
2022
with 37 others
Phase 2
192 of 547
15 open now
Registered
433rd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 443rd largest by enrollment of the 460 interventional ones that give a count, is one of 38 that started in 2022, is one of 192 in phase 2, and was the 433rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US

Read the detailed description

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in People Living with Human Immunodeficiency Virus (HIV) in the US

The four participants enrolled on version 3.0 protocol were terminated as the primary endpoint was revised from biopsy to an imaging-based approach in the subsequent protocol version 4.0. These changes were done due to recruiting challenges pertaining to biopsy. However, no participants were enrolled in the revised protocol (version 4.0) as, by then the decision to terminate the study was taken by the Sponsor considering the modifications in the internal R\&D focus and a revised commercialization strategy.

The version 3.0 protocol is dated 02/Jun/2022.

03

Conditions studied

  • Nonalcoholic Fatty Liver Disease

Keywords

  • Saroglitazar Magnesium
  • Nonalcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years of age) with documented .
  2. Documented diagnosis of NAFLD established by imaging (ultrasound, CT scan or MRI) or liver within 6 months before screening, based on American Association for the Study of Liver Disease [AASLD] criteria
  3. Hepatic fat fraction ≥8% by MRI-PDFF
  4. level ≥31 U/L in men and ≥19 U/L in women at Visit 1 and 2
  5. HIV-1 RNA \<200 copies/mL for ≥6 months on ART (must have screening HIV-1 RNA value and one clinical care value within 6 months prior to screening and up to the randomization that meets the criteria).
  6. Stable ART regimen for ≥3 months prior to screening and stable up to the randomization and no active plans to change ART while on study.
  7. Willingness to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. History of significant alcohol consumption (defined as >2 drinks/day on average for men, >1 drinks/day on average for women) for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening (Note 1: 1 drink =12 ounces of beer, 8-9 ounces of malt liquor, 4 ounces of wine or 1 ounce of spirits/hard liquor. Note 2: Use sex assigned at birth for alcohol consumption limits).
  2. History of other acute or chronic liver disease, including, but not limited to , primary biliary cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis, virus (HBV), and ongoing or recent (within the past 3 years) RNA positivity. (Exceptions: a. Participants with previously treated hepatitis C infection are eligible for consideration if their sustained virologic response was achieved more than 3 years prior to screening. The proportion of such participants in this trial will not exceed 25% of the study cohort. b. Participants with prior acute HBV infection that is resolved but currently do not have hepatitis B surface antigen (HBsAg) or detectable HBV DNA are eligible).
  3. History of liver transplant.
  4. Liver or radiologic imaging consistent with the clinical presence of cirrhosis or portal hypertension at screening.
  5. Participants whose Visit 2 , AST, or alkaline phosphatase (ALP) values exceed their Visit 1 values by more than 50%.

    Note: These participants will be required to have a third value measured at-least one week after V2, to assess for a trend. If the third value shows a continued increase ≥10% compared to the Visit 2 values, the participant is considered ineligible for randomization.

  6. Ongoing use of steatogenic medications or supra-physiologic hormonal therapies (Exception: transgender women on stable (≥3 month) feminizing hormonal therapy not excluded), within 3 months prior to screening until time of randomization or anticipated use of medications that cause significant changes in weight during the study period (Refer Appendix 7 of protocol for 'List of Steatogenic Medications Or Supra-Physiologic Hormonal Therapies Or Medications That Cause Significant Weight Change').
  7. Uncontrolled T2DM, defined as >9.5% at screening.
  8. Any of the following laboratory values at screening:

    1. ALT or AST >250 U/L
    2. Total >1.5 mg/dL and direct bilirubin > 0.5 mg/dL (unless due to Gilbert's disease or atazanavir use per the opinion of the site investigator)
    3. count \<150,000/mm3
    4. Estimated (e-GFR) \<60 mL/min/1.73m2 using the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation (Refer Appendix 6 of protocol for 'CKD-EPI Calculator')
    5. (INR) >1.3.
    6. Albumin \< 3.6 g/dL
  9. History of in the past 5 years and/or active neoplasm with the exception of superficial, non-melanoma, skin cancer.
  10. Unstable cardiovascular disease, including:

    1. Unstable angina, (i.e., new or worsening symptoms of coronary heart disease) and/or acute myocardial infarction within the 3 months preceding screening
    2. Acute coronary syndrome or coronary artery intervention within the 3 months preceding screening,
    3. Heart failure of (NYHA) class (III-IV) or worsening congestive heart failure within the 6 months preceding screening.
    4. History of (within 3 months preceding screening) or current unstable cardiac dysrhythmias.
    5. Uncontrolled hypertension (systolic blood pressure [SBP] >155 mmHg and/or diastolic blood pressure [DBP] >95 mmHg) at screening.
    6. Stroke or within the 6 months preceding screening.
  11. Unstable pulmonary disease (based upon site investigator's evaluation) at screening.
  12. Use of drugs that are known CYP2C8 inhibitors/substrates (Refer Appendix 2 of protocol for the 'List of Known CYP2C8 Inhibitors/Substrates') in the last 28 days prior to screening.
  13. History of severe illness or any other conditions that require systematic treatment/or hospitalization, until participant either completes therapy or is clinically stable on therapy as per the opinion of the investigator, for at least 7 days prior to screening (such as poorly controlled psychiatric disease, active gastrointestinal conditions that might interfere with drug absorption, etc.).
  14. Use of thiazolidinediones or Telmisartan within 3 months prior to screening or until time of randomization.
  15. Use of unstable doses of SGLT2 inhibitors (e.g. canagliflozin, empagliflozin, dapagliflozin, etc.), glucose-dependent insulinotropic polypeptide (GIP) and/or GLP-1 agonists (e.g. semaglutide, exenatide, liraglutide, lixisenatide, tirzepatide etc.) within 6 months prior to screening until time of randomization.
  16. Use of pentoxifylline, ursodeoxycholic acid, antioxidants such as vitamin E (>200 IU/day), glutathione, orlistat, betaine, or non-prescribed complementary alternative medications within 6 months prior to screening until time of randomization.
  17. Known allergy, sensitivity or intolerance to the study medication or formulation ingredients.
  18. History of any known bleeding disorder or coagulopathy.
  19. Any condition that in the opinion of the site investigator, would compromise the participant's ability to participate in the study.
  20. Unstable doses of anti-diabetic agents including sulfonylureas, biguanides or DPP-4 inhibitors in the last 3 months prior to screening until time of randomization.
  21. Unstable doses of lipid lowering agents such as statins (e.g. simvastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin, etc.) or fibrates (clofibrate, Fenofibrate) in the last 3 months prior to screening until time of randomization.
  22. Participant with weight change >5% within 6 months prior to screening until time of randomization.
  23. History of bariatric surgery or currently undergoing evaluation for bariatric surgery.
  24. Participation in another interventional clinical study and/or receipt of any other medication within 3 months prior to screening.
  25. History of COVID-19 infection in the last 30 days prior to screening.
  26. Pregnancy-related exclusions, include:

    1. Pregnant/lactating female (including positive pregnancy test at screening)
    2. Pregnancy should be avoided by male and female participants either by complete abstinence or the use of acceptable effective measures for the duration of the study and for at least 1 month after the end of the study treatment. Refer Appendix 3 Contraceptive Guidance 27. Participants having an absolute to MRI (eg., any implants, magnetic metals, cardiac pacemakers, neurostimulator) as per investigators' discretion
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Saroglitazar Magnesium 4 mg

    Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks)

    Drug: Saroglitazar Magnesium 4 mg

  • Placebo comparator
    Placebo Arm

    Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks).

    Drug: Placebo

Interventions

  • Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of treatment (24 weeks).

  • DrugPlacebo

    Subjects randomized to Placebo arm will receive Placebo treatment until the duration of treatment (24 weeks).

06

What researchers measure

Primary outcomes

  1. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Hepatic Fat Content Measured by MRI Proton Density Fat Fraction (MRI PDFF)

    Change from baseline in hepatic fat content

    Time frame: Week 24/EOT

Secondary outcomes

  1. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Reduction of Hepatic Fat Content as Measured by MRI PDFF.

    Proportion of participants with reduction of at least 30% in hepatic fat content from baseline

    Time frame: Week 24/EOT

  2. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/VCTE .

    Change from baseline in Liver Stiffness Measurement

    Time frame: Week 24/EOT

  3. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/VCTE

    Change from baseline in Continuous Controlled Attenuation Parameter

    Time frame: Week 24/EOT

  4. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/Vibration-controlled Transient Elastography (VCTE).

    Change from baseline in Fibroscan-aspartate aminotransferase (FAST) score

    Time frame: Week 24/EOT

  5. To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

    Change from baseline in plasma pro-collagen type 3 (PRO-C3) levels

    Time frame: Week 24/EOT

  6. To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

    Change from baseline in Fibrois-4 index (FIB-4) This index is based on age, platelet count, ALT level, and AST level. FIB-4 was calculated using the following formula: FIB4 = (Age (years) x AST (U/L))/(Platelet count (10\^9/L) x √ALT (U/L)). A decrease in FIB-4 represents a positive outcome. A FIB-4 Index of \<1.45 indicates none to moderate fibrosis and an Index of \>3.25 indicates advanced fibrosis.

    Time frame: Week 24/EOT

  7. To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

    Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis

    Time frame: Week 24/EOT

  8. To Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

    Change from baseline in Nonalcoholic fatty liver disease Fibrosis Score (NFS) The NFS is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. NFS was calculated using the following formula: NAFLD fibrosis score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A decrease in NFS score represents a positive outcome. An NFS score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis.

    Time frame: Week 24/EOT

  9. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Liver Enzyme

    Change from baseline in liver enzyme parameters (ALT and AST)

    Time frame: Week 24/EOT

  10. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Lipid Profile

    Change from baseline in triglyceride \[TG), high-density lipoprotein \[HDL\], low-density lipoprotein \[LDL\], very low-density lipoprotein \[VLDL\], total cholesterol, and non-HDL cholesterol

    Time frame: Week 24/EOT

  11. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Fasting Glucose

    Change from baseline in fasting plasma glucose (FPG)

    Time frame: Week 24/EOT

  12. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.

    Change from baseline in body weight

    Time frame: Week 24/EOT

  13. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.

    Change from baseline in BMI

    Time frame: Week 24/EOT

  14. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.

    Change from baseline in hip circumference and minimum waist circumference

    Time frame: Week 24/EOT

  15. To Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Health-related Quality of Life Scores Measured by Short Form-36 (SF-36) Questionnaire.

    Change from baseline in SF-36 Questionnaire mental (MCS) and physical components scores (PCS). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status.

    Time frame: Week 24/EOT.

Other outcomes

  1. Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium Compared to Placebo

    Number of Participants with Adverse Events. We have included data for Treatment emergent adverse events (TEAEs) only. TEAEs are those AEs that occur after administration of the study drug.

    Time frame: From baseline to Week 28

07

Results

Posted Jul 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneSaroglitazar Magnesium 4 mgPlacebo Arm
Started31
Completed00
Not completed31
Withdrew: Study terminated31

Outcome measures

PrimaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Hepatic Fat Content Measured by MRI Proton Density Fat Fraction (MRI PDFF)

Change from baseline in hepatic fat content

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Reduction of Hepatic Fat Content as Measured by MRI PDFF.

Proportion of participants with reduction of at least 30% in hepatic fat content from baseline

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/VCTE .

Change from baseline in Liver Stiffness Measurement

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/VCTE

Change from baseline in Continuous Controlled Attenuation Parameter

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in FibroScan®/Vibration-controlled Transient Elastography (VCTE).

Change from baseline in Fibroscan-aspartate aminotransferase (FAST) score

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

Change from baseline in plasma pro-collagen type 3 (PRO-C3) levels

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

Change from baseline in Fibrois-4 index (FIB-4) This index is based on age, platelet count, ALT level, and AST level. FIB-4 was calculated using the following formula: FIB4 = (Age (years) x AST (U/L))/(Platelet count (10\^9/L) x √ALT (U/L)). A decrease in FIB-4 represents a positive outcome. A FIB-4 Index of \<1.45 indicates none to moderate fibrosis and an Index of \>3.25 indicates advanced fibrosis.

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effects of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Non-invasive Markers of Fibrosis and Steatosis

Change from baseline in Nonalcoholic fatty liver disease Fibrosis Score (NFS) The NFS is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. NFS was calculated using the following formula: NAFLD fibrosis score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A decrease in NFS score represents a positive outcome. An NFS score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis.

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Liver Enzyme

Change from baseline in liver enzyme parameters (ALT and AST)

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Lipid Profile

Change from baseline in triglyceride \[TG), high-density lipoprotein \[HDL\], low-density lipoprotein \[LDL\], very low-density lipoprotein \[VLDL\], total cholesterol, and non-HDL cholesterol

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Fasting Glucose

Change from baseline in fasting plasma glucose (FPG)

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.

Change from baseline in body weight

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.

Change from baseline in BMI

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Anthropometric Measurements.

Change from baseline in hip circumference and minimum waist circumference

Time frame:
Week 24/EOT

No measurements were reported for this outcome.

SecondaryTo Evaluate the Effect of Saroglitazar Magnesium 4 mg Compared With Placebo on Changes in Health-related Quality of Life Scores Measured by Short Form-36 (SF-36) Questionnaire.

Change from baseline in SF-36 Questionnaire mental (MCS) and physical components scores (PCS). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status.

Time frame:
Week 24/EOT.

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium Compared to Placebo

Number of Participants with Adverse Events. We have included data for Treatment emergent adverse events (TEAEs) only. TEAEs are those AEs that occur after administration of the study drug.

Time frame:
From baseline to Week 28
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium Compared to Placebo
ParticipantsSaroglitazar Magnesium 4 mgPlacebo Arm
Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium Compared to Placebo00

Adverse events

Collected over From Baseline to Week 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saroglitazar Magnesium 4 mg0/3 (0%)0/3 (0%)0/3 (0%)
Placebo Arm0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventSaroglitazar Magnesium 4 mgPlacebo Arm
Upper Respiratory tract InfectionRespiratory, thoracic and mediastinal disorders0/31/1

Baseline characteristics

Safety Population

Age, Categorical
Age, Categorical(Participants)Saroglitazar Magnesium 4 mgPlacebo ArmTotal
<=18 years000
Between 18 and 65 years213
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)Saroglitazar Magnesium 4 mgPlacebo ArmTotal
Female000
Male314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saroglitazar Magnesium 4 mgPlacebo ArmTotal
Hispanic or Latino213
Not Hispanic or Latino101
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Saroglitazar Magnesium 4 mgPlacebo ArmTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Saroglitazar Magnesium 4 mgPlacebo ArmTotal
United States314
08

Study locations

8 sites
  • Zydus US004
    Birmingham, Alabama 35294-2050, United States
  • Zydus US005
    La Jolla, California 92037, United States
  • Zydus US006
    San Francisco, California 94143, United States
  • Zydus US002
    Indianapolis, Indiana 46202, United States
  • Zydus US003
    Baltimore, Maryland 21287, United States
  • Zydus US001
    Durham, North Carolina 27710, United States
  • Zydus US007
    Houston, Texas 77030, United States
  • Zydus US008
    Richmond, Virginia 23298, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Oct 2023, 9 months.

Results were first posted in Jul 2025, 1 year 9 months after primary completion. A results delay was requested in Oct 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Jan 27, 2022
StartActual
Dec 8, 2022
Primary completionActual
Oct 2, 2023
CompletionActual
Oct 2, 2023
Results delay requested
Oct 1, 2024
Results first posted
Jul 16, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05211284
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Dec 8, 2022
Primary completion
Oct 2, 2023
Completion
Oct 2, 2023
Results posted
Jul 16, 2025
Last update
Sep 2, 2025

Study contacts

Deven V Parmar
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion